Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study

被引：69

作者：

Hu, Jiao ^{[1
,2
]}

Chen, Jinbo ^{[1
,2
]}

Ou, Zhenyu ^{[1
,2
,4
]}

Chen, Haige ^{[3
]}

Liu, Zheng

Chen, Minfeng ^{[1
,2
]}

Zhang, Ruiyun ^{[3
]}

Yu, Anze ^{[5
]}

Cao, Rui ^{[6
]}

Zhang, Enchong ^{[7
]}

Guo, Xi ^{[8
]}

Peng, Bo ^{[9
]}

Deng, Dingshan ^{[1
,2
]}

Cheng, Chunliang ^{[1
,2
]}

Liu, Jinhui ^{[1
,2
]}

Li, Huihuang ^{[1
,2
]}

Zou, Yihua ^{[10
]}

Deng, Ruoping ^{[11
]}

Qin, Gang ^{[11
]}

Li, Wenze

Wang, Lue ^{[12
,13
]}

Chen, Tao ^{[14
]}

Pei, Xiaming ^{[15
]}

Gong, Guanghui ^{[16
]}

Tang, Jiansheng ^{[17
]}

Othmane, Belaydi ^{[1
,2
]}

Cai, Zhiyong ^{[1
,2
]}

Zhang, Chunyu ^{[1
,2
]}

Liu, Zhi ^{[1
,2
]}

Zu, Xiongbing ^{[1
,2
]}

机构：

[1] Cent South Univ, Xiangya Hosp, Dept Urol, Changsha, Peoples R China

[2] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China

[3] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China

[4] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Urol, Wuhan, Peoples R China

[5] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Peoples R China

[6] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing, Peoples R China

[7] China Med Univ, Shengjing Hosp, Dept Urol, Shenyang, Peoples R China

[8] Hunan Normal Univ, Hunan Prov Peoples Hosp, Affiliated Hosp 1, Dept Urol, Changsha, Peoples R China

[9] Zhangjiajie Peoples Hosp, Dept Urol, Zhangjiajie, Peoples R China

[10] First Peoples Hosp Chenzhou, Dept Urol, Chenzhou, Peoples R China

[11] Cent Hosp Yongzhou, Dept Urol, Yongzhou, Peoples R China

[12] First Peoples Hosp Xiangtan City, Dept Urol, Xiangtan, Peoples R China

[13] Huarong Peoples Hosp, Dept Urol, Yueyang, Peoples R China

[14] Xiangyang Cent Hosp, Dept Urol, Xiangyang, Peoples R China

[15] Hunan Canc Hosp, Dept Urol, Changsha, Peoples R China

[16] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha, Peoples R China

[17] Xiangnan Univ, Affiliated Hosp, Dept Urol, Chenzhou, Peoples R China

来源：

CELL REPORTS MEDICINE | 2022年 / 3卷 / 11期

基金：

中国国家自然科学基金; 湖南省自然科学基金;

关键词：

PHASE-III TRIAL; UROTHELIAL CARCINOMA; TUMOR MICROENVIRONMENT; OPEN-LABEL; END-POINT; PEMBROLIZUMAB; CISPLATIN; OUTCOMES; TISLELIZUMAB; ATEZOLIZUMAB;

D O I：

10.1016/j.xcrm.2022.100785

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination therapy (tislelizumab + GC) in patients with mus-cle-invasive bladder cancer (MIBC) and explore the efficacy predictors, we perform a multi-center, real-world cohort study that enrolls 253 patients treated with neoadjuvant treatments (combination therapy: 98, chemo-therapy: 107, and immunotherapy: 48) from 15 tertiary hospitals. We demonstrate that neoadjuvant combi-nation therapy achieves the highest complete response rate and pathological downstaging rate compared with neoadjuvant immunotherapy or chemotherapy. We develop and validate an efficacy prediction model consisting of pretreatment clinical characteristics, which can pinpoint candidates to receive neoadjuvant combination therapy. We also preliminarily reveal that patients who achieve pathological complete response after neoadjuvant treatments plus maximal transurethral resection of the bladder tumor may be safe to receive bladder preservation therapy. Overall, this study highlights the benefit of neoadjuvant combination therapy based on tislelizumab for MIBC.

引用

页数：17

共 50 条

[21] Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer
Macleod, Liam C.
Fam, Mina M.
Yabes, Jonathan G.
Hale, Nathan E.
Turner, Robert M., II
Lopa, Samia H.
Gingrich, Jeffrey R.
Borza, Tudor
Skolarus, Ted A.
Davies, Benjamin J.
Jacobs, Bruce L.
CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : 201 - +
[22] Immunotherapy in neoadjuvant setting in muscle-invasive bladder cancer, what's new?
Alkassis, Marwan
Sarkis, Julien
Tayeh, Georges Abi
Kourie, Hampig Raphael
Nemer, Elie
IMMUNOTHERAPY, 2021, 13 (06) : 459 - 463
[23] Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer
Ajib, Khaled
Tjong, Michael C.
Tan, Guan Hee
Nason, Gregory
Berjaoui, Mohammad Baker
Erlich, Annette
Maganti, Manjula
Sridhar, Srikala
Fleshner, Neil E.
Zlotta, Alexandre R.
Catton, Charles
Berlin, Alejandro
Chung, Peter
Kulkarni, Girish S.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (12): : 404 - 410
[24] Efficacy and safety analysis of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer
Yu, Yanhang
Zhang, Chuanao
Chen, Hao
Zhang, Jianglei
Ouyang, Jun
Zhang, Zhiyu
FRONTIERS IN IMMUNOLOGY, 2024, 15
[25] Neoadjuvant chemotherapy for muscle-invasive bladder cancer: does variant histology matter?
Catarino, Raquel
Alves, Luisa
Pereira, Diogo
Costa, Gabriel
Pereira, Joao
Cardoso, Andre
Braga, Isaac
Freitas, Rui
Correia, Tiago
Cerqueira, Manuel
Reis, Frederico Carmo
Lobo, Francisco
Silva, Vitor
Magalhaes, Sanches
Morais, Antonio
Prisco, Rui
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (12) : 3163 - 3169
[26] Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?
Niegisch, Guenter
Lorch, Anja
Droller, Michael J.
Lavery, Hugh J.
Stensland, Kristian D.
Albers, Peter
EUROPEAN UROLOGY, 2013, 64 (03) : 355 - 357
[27] Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions
Porras, Vicenc Ruiz de
Pardo, Juan Carlos
Etxaniz, Olatz
Font, Albert
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 178
[28] Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A new standard of care?
Harland, S
BJU INTERNATIONAL, 2003, 92 (09) : 877 - 878
[29] Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
Miyagi, Hiroko
Kwenda, Elizabeth
Ramnaraign, Brian H.
Chatzkel, Jonathan A.
Brisbane, Wayne G.
O'Malley, Padraic
Crispen, Paul L.
CANCERS, 2023, 15 (01)
[30] Impact of neoadjuvant chemotherapy on therapeutic management of muscle-invasive bladder cancer
Meyer, V.
Flechon, A.
Tartas, S.
Fassi-Fehri, H.
Ruffion, A.
Martin, X.
Colombel, M.
PROGRES EN UROLOGIE, 2015, 25 (02): : 83 - 89

← 1 2 3 4 5 →